Press Releases

Recent news published by Zetagen

Zetagen Announces the Appointment of Debasish (Debu) Tripathy M.D. to its Advisory Board

Syracuse, New York, March 18, 2024 – Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company dedicated to developing breakthrough therapies via local administration for the treatment of metastatic and primary cancers in bone and soft tissue organs, today announced the appointment of Debasish (Debu) Tripathy, MD to its advisory board. Dr. Tripathy is Professor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Zetagen Receives Approval in Australia to Begin Pilot Study of ZetaFuse® Bone Graft to Treat Cervical Degenerative Disc Disease

November 6, 2023, (Syracuse, New York) - Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company focused on driving breakthrough innovation in the treatment of metastatic cancers to bone and soft tissue organs as well as osteologic interventions, today announced its approval from the Human Research Ethics Committee (HREC) of Australia to begin a pilot study using its novel therapy ZetaFuse® bone graft for the treatment of cervical degenerative disc disease. The pilot study is a randomized, open-label, two-level cervical program which will examine the safety and efficacy of ZetaFuse® bone graft in patients undergoing anterior cervical discectomy and fusion (ADCF) surgery.

Zetagen Announces Publication in Pain Management of Early Data Using ZetaMet™ (Zeta-BC-003) as a Potential Treatment for Bone Metastases

October 10, 2023, (Syracuse, New York) - Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company focused on driving breakthrough innovation in the treatment of metastatic cancers to bone and soft tissue organs as well as osteologic interventions, today announced publication of early, human clinical data in the peer-reviewed journal Pain Management on ZetaMet™ (Zeta-BC-003) for the treatment bone metastases.

Zetagen Therapeutics Secures 9.79 Million USD Series B Funding Raise for Advancement of ZetaMet™ (Zeta-BC-003) and ZetaMAST™ (Zeta-MBC-005)for Treatment of Metastatic Bone and Soft Tissue Lesions

August 11, 2023 - (Syracuse, New York) - Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company focused on driving breakthrough innovation in the treatment of metastatic cancers to bone and soft tissue organs as well as osteologic interventions, today announced the close of $9.79 million USD Series B funding round.

ZetaMet™ (Zeta-BC-003) Receives Health Canada Authorization for Phase 2a Study in Treating Metastatic Bone Lesions

January 18, 2022 – (Syracuse, New York) – Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, today announced it has received authorization from Health Canada to conduct a Phase 2a study, examining the safety and efficacy of ZetaMet™ (Zeta-BC-003) for the treatment of metastatic bone lesions.

Zetagen Therapeutics Awarded $2 Million USD Grant from the National Cancer Institute (NCI) for Phase 2 Study of ZetaMet™ (Zeta-BC-003) for Treatment of Metastatic Bone Cancers

December 13, 2021 – (Syracuse, New York) – Zetagen Therapeutics, Inc., a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, today announced it has received a two year, $2 million USD grant from the National Cancer Institute of the National Institutes of Health (NIH).

ZetaMet™ (Zeta-BC-003) Receives Breakthrough Device Designation from U.S. Food and Drug Administration (FDA) for Treatment of Metastatic Bone Cancers

December 1, 2021 – (Syracuse, New York) – Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, today announced it has received Breakthrough Device designation from the Centers for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) for its ZetaMet™ (Zeta-BC-003) technology.

Zetagen Therapeutics, Inc. Announces European Patent for the Treatment of Stimulating Bone Growth

April 28, 2021 – (Syracuse, New York) - Zetagen Therapeutics, Inc. a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions today announced that the European Patent Office issued Patent. No. 3148517 to the Company.

Zetagen Therapeutics, Inc. Receives Australian Patent Issuance for Treatment of Stimulating Bone Growth

July 23, 2020 – (Syracuse, New York) - private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and orthopedic interventions, announced today that the Australian Government has issued Patent No. 2015267006 to the Company. The patent, entitled Composition and Methods to Promote Bone Formation, covers the use of methods for stimulating bone growth using the Company’s small molecule, ZetaMet™ (Zeta-BC-003).